THALES
16.4.2024 09:01:32 CEST | Business Wire | Press release
Thales, the cybersecurity leader that protects critical applications, APIs, and data, anywhere at scale, today announced the release of the 2024 Imperva Bad Bot Report, a global analysis of automated bot traffic across the internet. Nearly half (49.6%) of all internet traffic came from bots in 2023—a 2% increase over the previous year, and the highest level Imperva has reported since it began monitoring automated traffic in 2013.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416225637/en/
©Thales
For the fifth consecutive year, the proportion of web traffic associated with bad bots grew to 32% in 2023, up from 30.2% in 2022, while traffic from human users decreased to 50.4%. Automated traffic is costing organizations billions (USD) annually due to attacks on websites, APIs, and applications.
“Bots are one of the most pervasive and growing threats facing every industry,” says Nanhi Singh, General Manager, Application Security at Imperva, a Thales company. “From simple web scraping to malicious account takeover, spam, and denial of service, bots negatively impact an organization’s bottom line by degrading online services and requiring more investment in infrastructure and customer support. Organizations must proactively address the threat of bad bots as attackers sharpen their focus on API-related abuses that can lead to account compromise or data exfiltration.”
Key trends identified in the 2024 Imperva Bad Bot Report include:
- Global average of bad bot traffic reached 32%: Ireland (71%), Germany (67.5%), and Mexico (42.8%), saw the highest levels of bad bot traffic in 2023. The US also saw a slightly higher ratio of bad bot traffic at 35.4% compared to 2022 (32.1%).
- Growing use of generative AI connected to the rise in simple bots: Rapid adoption of generative AI and large language models (LLMs) resulted in the volume of simple bots increasing to 39.6% in 2023, up from 33.4% in 2022. The technology uses web scraping bots and automated crawlers to feed training models, while enabling nontechnical users to write automated scripts for their own use.
- Account takeover is a persistent business risk: Account takeover (ATO) attacks increased 10% in 2023, compared to the same period in the prior year. Notably, 44% of all ATO attacks targeted API endpoints, compared to 35% in 2022. Of all login attempts across the internet, 11% were associated with account takeover. The industries that saw the highest volume of ATO attacks in 2023 were Financial Services (36.8%), Travel (11.5%), and Business Services (8%).
- APIs are a popular vector for attack: Automated threats caused a significant 30% of API attacks in 2023. Among them, 17% were bad bots exploiting business logic vulnerabilities—a flaw within the API’s design and implementation that allows attackers to manipulate legitimate functionality and gain access to sensitive data or user accounts. Cybercriminals use automated bots to find and exploit APIs, which act as a direct pathway to sensitive data, making them a prime target for business logic abuse.
- Every industry has a bot problem: For a second consecutive year, Gaming (57.2%) saw the largest proportion of bad bot traffic. Meanwhile, Retail (24.4%), Travel (20.7%), and Financial Services (15.7%) experienced the highest volume of bot attacks. The proportion of advanced bad bots, those that closely mimic human behavior and evade defenses, was highest on Law & Government (75.8%), Entertainment (70.8%), and Financial Services (67.1%) websites.
- Bad bot traffic originating from residential ISPs grows to 25.8%: Early bad bot evasion techniques relied on masquerading as a user agent (browser) commonly used by legitimate human users. Bad bots masquerading as mobile user agents accounted for 44.8% of all bad bot traffic in the past year, up from 28.1% just five years ago. Sophisticated actors combine mobile user agents with the use of residential or mobile ISPs. Residential proxies allow bot operators to evade detection by making it appear as if the origin of the traffic is a legitimate, ISP-assigned residential IP address.
“Automated bots will soon surpass the proportion of internet traffic coming from humans, changing the way that organizations approach building and protecting their websites and applications,” continued Singh. “As more AI-enabled tools are introduced, bots will become omnipresent. Organizations must invest in bot management and API security tools to manage the threat from malicious, automated traffic.”
Additional Information:
- Download a copy of the 2024 Imperva Bad Bot Report for additional insights.
- See how Imperva Advanced Bot Protection, API Security, and Client-Side Protection can protect websites, mobile applications, and APIs from automated attacks and fraud without affecting the flow of business-critical traffic.
- Read the Imperva Blog for the latest product and solution news, and threat intelligence from Imperva Threat Research.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416225637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
